A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis

The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.

Start Date07 Jul 2025

Sponsor / Collaborator

Leo Pharma, Inc.

JPRN-jRCTs031240119

/ RecruitingNot ApplicableIIT

Efficacy of Delgocitinib ointment and topical corticosteroids combination therapy in pediatric patients with atopic dermatitis in remission induction

Start Date13 Jun 2024

Sponsor / Collaborator

Torii Pharmaceutical Co., Ltd.

JPRN-jRCT2031230713

/ RecruitingPhase 3IIT

Phase III Clinical Study of JTE-052 new drug product - Bioequivalence study between new drug product and JTE-052 ointment in patients with atopic dermatitis -

Start Date22 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Delgocitinib

100 Translational Medicine associated with Delgocitinib

100 Patents (Medical) associated with Delgocitinib

124

Literatures (Medical) associated with Delgocitinib

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Topical delgocitinib for the treatment of chronic hand eczema

Review

Author: Yilmaz, Orhan ; Torres, Tiago ; Elshaikh Berair, Mohamed ; Abdelhalim, Asaad

PURPOSE:

Chronic hand eczema (CHE) is a prevalent dermatological condition characterized by significant morbidity and impaired quality of life. Delgocitinib, a pan-JAK inhibitor, has emerged as a promising topical treatment for CHE, targeting key cytokine-mediated inflammatory pathways involved in the disease. Delgocitinib 20 mg/g (2%) cream was approved by the European Medicines Agency (EMA) in 2024 for moderate-to-severe CHE, and its U.S. Food and Drug Administration (FDA) review is currently in progress.

MATERIALS AND METHODS:

PubMed, Medline and ClinicalTrials.gov were searched up to January 21, 2025, using specific search terms related to delgocitinib and chronic hand eczema.

RESULTS AND CONCLUSIONS:

Clinical trials have demonstrated its effectiveness in improving disease severity, including eczema signs and symptoms such as pain and itching, and enhancing patient-reported outcomes compared to vehicle. Topical delgocitinib has shown a favorable safety profile, with most adverse events being mild and unrelated to treatment. Serious adverse events were rare, and treatment discontinuation due to adverse events was minimal. This narrative review synthesizes current evidence on topical delgocitinib's clinical utility and safety in CHE, positioning it as a valuable therapeutic option. Further comparative studies are needed to evaluate its efficacy against oral JAK inhibitors and other topical immunosuppressants, providing insight into optimizing treatment strategies for this chronic condition.

01 Jul 2025·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Article

Author: Bissonnette, Robert ; Agner, Tove ; Plohberger, Ursula ; Schliemann, Sibylle ; Ferrucci, Silvia ; Serra-Baldrich, Esther ; Worm, Margitta ; Warren, Richard B ; Molin, Sonja ; Stingeni, Luca ; Silverberg, Jonathan I ; Balita-Crisostomo, Cherry Lou ; Østerdal, Marie Louise ; Crépy, Marie-Noëlle ; Schuttelaar, Marie-Louise ; Gooderham, Melinda

BACKGROUND:

Delgocitinib cream is the only topical treatment that has been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE).

OBJECTIVE:

The objective of this trial was to evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g as needed for 36 weeks in adults with CHE.

METHODS:

In phase 3 open-label DELTA 3 (NCT04949841), patients who completed the 16-week treatment period in the DELTA 1 and 2 trials were treated on an as-needed basis with twice-daily delgocitinib cream for 36 weeks (n= 801). Patients with Investigator's Global Assessment for CHE (IGA-CHE) ≥2 received treatment until IGA-CHE ≤1 was achieved. The primary endpoint was the number of treatment-emergent adverse events. Key secondary endpoints were IGA-CHE 0/1 and ≥75%/≥90% improvement in Hand Eczema Severity Index (HECSI-75/90) scores.

RESULTS:

Delgocitinib was well-tolerated (n= 801; R = 231.1; patient years of observation = 535.7), with most frequent adverse events being COVID-19 and nasopharyngitis. DELTA 3 baseline IGA-CHE 0/1 (24.6%) and HECSI-75/HECSI-90 (51.8%/31.8%) were maintained to week 36 (30.0% and 58.6%/36.6%, respectively) among delgocitinib-treated patients in the parent trials. Among those previously treated with cream vehicle, corresponding response rates improved from DELTA 3 baseline (9.1% and 23.7%/12.0%, respectively) to week 36 (29.5% and 51.5%/35.7%).

LIMITATIONS:

Open-label trial.

CONCLUSION:

Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in patients with CHE for up to 52 weeks.

27 Jun 2025·ORGANIC LETTERS

Stereoselective Synthesis of Delgocitinib and Its Diastereomer Using Organocatalyzed Michael Addition

Article

Author: Yokoshima, Satoshi ; Tsutsumi, Ken ; Umekubo, Nariyoshi ; Matsuzaki, Haruo ; Morita, Kaito

Herein, we describe the stereoselective synthesis of delgocitinib and its diastereomer. Delgocitinib, a Janus kinase (JAK) inhibitor, is characterized by a diaza-spirocyclic structure consisting of pyrrolidine and azetidine rings. The organocatalyzed Michael addition of propanal with fumarate or maleimide facilitated the formation of contiguous tertiary stereogenic centers, leading to the stereoselective production of each diastereomer. Intramolecular C-H amination reactions introduced a nitrogen atom on one of the tertiary carbons, and subsequent azetidine formation constructed the spirocyclic system.

News (Medical) associated with Delgocitinib

03 Jun 2025

·pipelinereview.com

LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)

BALLERUP, Denmark I June 03, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP). PPP is the first disease for which LEO Pharma will investigate delgocitinib cream since completion of the Phase 3 DELTA trials in Chronic Hand Eczema (CHE). “ The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey of delgocitinib cream,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma. “PPP is a disease with few treatment options that can severely affect quality of life. We are hopeful that this therapy could potentially provide much-needed help for patients suffering from this devastating condition.” PPP is an uncommon, chronic, inflammatory, relapsing skin disease characterized by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet. 3,4 PPP is associated with a high patient burden, resulting in significant impairment of quality of life. Patients often experience pain, fatigue, and the condition can be triggered by factors such as smoking, infections, and stress. PPP is associated with comorbidities such as thyroid dysfunction and metabolic syndrome. 4 There are currently no approved advanced systemic treatments for PPP in the U.S. or Europe. 5 PPP is associated with complex T-cell activation patterns, which may be why many biologics that target individual T helper cell populations have shown limited efficacy in clinical trials. 6 Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor shown to inhibit the activity of all four JAKs, which are involved in inflammatory signaling. 1,2 Using delgocitinib cream’s mechanism of action, the trial will investigate the potential benefit of inhibiting multiple JAKs to treat PPP. “I’ve seen firsthand how PPP can severely disrupt patients’ lives, making it painful to walk, perform activities of daily living and impacting their ability to work,” said Dr. Robert Bissonnette, international coordinating investigator (ICI) on the DELTA NEXT trial and Chairman at Innovaderm Montreal, Canada . “Despite the significant burden it places on patients, treatment options remain limited. There is a real and urgent need for effective therapies.” The DELTA NEXT trial plans to recruit up to 135 patients with active, chronic, mild to severe PPP for whom topical corticosteroids are inadequate or inadvisable. Participants will be recruited across 40-45 sites in the United States, Canada, the United Kingdom, Germany, and Poland. Currently, delgocitinib cream is approved for adults in the European Union, United Kingdom, Switzerland, and the United Arab Emirates for the treatment of moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate, and is under review in other markets, including the United States. For more information on the DELTA NEXT trial, go to clinicaltrials.gov . Notes to editors About Delgocitinib Cream Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor. It prevents the activation of the JAK-STAT pathway by blocking the signaling of several inflammatory cytokines, thereby suppressing the inflammatory cascade and preventing the downregulation of important barrier genes. 7 Delgocitinib cream is currently approved in the European Union, the United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. It is under review in other markets, including the United States. In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. About the DELTA NEXT Trial DELTA NEXT is a phase 2a, randomized, double-blind, two-arm, vehicle control, adaptive design proof-of-concept trial to assess the efficacy and safety of twice-daily delgocitinib cream compared with cream vehicle in adult subjects with mild to severe PPP. The DELTA NEXT trial plans to recruit up to 135 patients with active, chronic, mild to severe PPP for whom topical corticosteroids are inadequate or inadvisable. Participants will be randomized into a 2:1 ratio to receive either delgocitinib cream or cream vehicle. Participants will be recruited across 40-45 sites in the United States, Canada, the United Kingdom, Germany, and Poland. About Palmoplantar Pustulosis (PPP) Palmoplantar Pustulosis (PPP) is an uncommon chronic, inflammatory, relapsing skin disease characterized by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet. 3,4 The disease is more common in females, with the estimated prevalence ranging from 0.01% to 0.05%. 3,4 The mean age of patients ranges from 40 to 58 years and is often associated with smoking, thyroid-gland abnormalities, and nickel sensitivity. 4,8 PPP is associated with a significant clinical burden. Patients often experience pain, fatigue, and the condition can be associated with hyperlipidemia and high blood pressure. 8 The condition has been shown to have a greater impairment on work and daily life than plaque psoriasis. 8 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com . References SOURCE: LEO Pharma

Phase 2Phase 3Drug ApprovalLicense out/in

15 May 2025

·www.businesswire.com

Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16%

BALLERUP, Denmark--(BUSINESS WIRE)--In Q1, LEO Pharma continued its robust growth, driven by dermatology, and made significant strategic progress. This included expanding the launch of Anzupgo® to five markets, advancing innovation through the newly formed strategic partnership with Gilead for the STAT6 program, and significantly improving profitability with a return to a positive net profit. Q1 2025 highlights LEO Pharma’s revenue increased by 10% year-on-year to DKK 3,373 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (+45% at CER), with Europe (+2% at CER) and Rest of World (+5% at CER) also contributing to the overall growth. Dermatology portfolio revenue grew by 10% (CER) year-on-year, driven by the Strategic brands, Adtralza®/Adbry® and Anzupgo®, which together saw a revenue increase of 73% (CER). Sales in the Thrombosis portfolio declined by 1% (CER) year-on-year, negatively impacted by order timing. Operating profit improved significantly, with adjusted EBITDA reaching DKK 545 million in Q1 2025, reflecting a margin of 16% (Q1 2024: 8%) excluding the upfront payment from Gilead and other non-recurring items. Net profit for the quarter was DKK 1,742 million (Q1 2024: negative DKK 366 million), including non-recurring items. Free cash flow was positive DKK 1,386 million for Q1 2025 (Q1 2024: negative DKK 571 million), and net interest-bearing debt was reduced to DKK 9,750 million (YE 2024: DKK 11,115 million). Excluding one off M&A-related payments, free cash flow in Q1 2025 was negative DKK 241 million. In Q1, LEO Pharma reported positive results from the DELTA TEEN and DELTA China trials, marking the fifth and sixth consecutive successful phase 3 trials for delgocitinib (brand name: Anzupgo®) in chronic hand ezcema. Additionally, in January, LEO Pharma announced a strategic partnership with Gilead Sciences to accelerate the pre-clinical STAT6 program. The 2025 financial outlook for revenue growth of 6-9% (CER) and an adjusted EBITDA margin of 15-18% is unchanged and confirmed. "We have seen a good start to 2025, with encouraging progress in the ongoing launch of Anzupgo® and key milestones achieved for our innovation pipeline. A significant highlight is the acceleration of the STAT6 program through our new partnership with Gilead. Additionally, the return to a positive net result marks another key milestone for the quarter, as we continue to develop the foundations for LEO Pharma’s long-term financial strength,” says Christophe Bourdon, CEO of LEO Pharma. Q1 2025 Financial overview (DKK million) Q1 2025 Q1 2024 Growth as reported Revenue 3,373 3,064 10% Revenue growth at CER 9% 13% N.m. Adjusted EBITDA 545 257 112% Net profit /(loss) for the period 1,742 (366) N.m. About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com

Financial StatementClinical ResultPhase 3

24 Apr 2025

·www.businesswire.com

LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet

TORONTO--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, is pleased to share that The Lancet, which is considered one of the most influential peer-reviewed medical journals in the world, has published an article discussing the findings of the DELTA FORCE trial for investigational delgocitinib cream. The publication summarizes the results of DELTA FORCE, a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with alitretinoin capsules.1 Alitretinoin is the only treatment currently approved in Canada to treat severe CHE in patients who do not respond to topical corticosteroids.2 In Canada and the US, delgocitinib cream is currently under review and has not been approved by Health Canada or the FDA. Delgocitinib cream achieved the primary outcome measure of the DELTA FORCE trial, assessing the Hand Eczema Severity Index (HECSI) scores from baseline to Week 12 compared to alitretinoin capsules. Delgocitinib cream also met all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, a reduction in HECSI scores from baseline to Week 24, and improvement in health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI). Furthermore, patients receiving delgocitinib cream had fewer treatment-emergent adverse events (AEs) compared to those receiving alitretinoin capsules. “The discussion of delgocitinib and the presentation of DELTA FORCE data in The Lancet is an exciting moment for the LEO Pharma team,” said Robert Spurr, EVP, LEO Pharma, North America and President, LEO Pharma, US. “We are proud to contribute to the overall understanding of moderate to severe chronic hand eczema, helping uncover potentially new treatment options for those living with skin conditions like CHE.” “We know that CHE is an under researched condition,” commented Dr. Charles Lynde, Chief Medical Director, The Lynde Institute for Dermatology & Lynderm Research Inc. and Associate Professor, University of Toronto, Department of Medicine. “We hope that discussions of the DELTA FORCE program, like that published in The Lancet, will continue to raise awareness of the disease, inspire new research, and ultimately help improve the quality of life of those living with CHE.” About The Lancet The Lancet is a world-leading source of clinical, public health, and global health knowledge. Lancet journals have an extensive global reach with more than 36.6 million annual visits and 108.1 million downloaded articles.3 About the DELTA FORCE Trial DELTA FORCE was a 24-week, randomized, assessor-blinded, active-controlled, parallel-group, phase 3, two-arm trial to compare the efficacy and safety of delgocitinib cream twice-daily with alitretinoin capsules once-daily in adult participants with severe chronic hand eczema.1 The primary endpoint of the trial was the change in Hand Eczema Severity Index (HECSI) score from baseline to Week 12. Participants assigned to receive delgocitinib cream applied the drug to the skin twice a day for 16 weeks. Participants assigned to receive alitretinoin capsules took the drug orally once a day for 12 weeks. All participants were permitted to continue for up to 24 weeks if the doctor considered that they were benefiting from the treatment.1 All 14 North American DELTA FORCE clinical trial sites were located in Canada.4 About Chronic Hand Eczema Chronic Hand Eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.5,6 HE is the most common skin disorder of the hands7 with a prevalence rate of approximately 4.7%.8 In a substantial number of patients, HE can develop into a chronic condition.7 CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,9 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition.10 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.11 About delgocitinib cream Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.12 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.13 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. Delgocitinib cream is currently approved and marketed under the trade name Anzupgo® in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. Delgocitinib is under investigation in Canada and the United States. About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com. LEO Pharma Canada is located in Toronto, Ontario. References: 1 ClinicalTrials.gov. National Library of Medicine (U.S.). A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema. Identifier: NCT05259722. https://classic.clinicaltrials.gov/ct2/show/NCT05259722. 2 Thyssen JP, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022;86:357–378. 3 The Lancet. About The Lancet. Published: 2024. Last assessed: Jun 25, 2024. Available at: https://www.thelancet.com/lancet/about. 4 Giménez-Arnau, Ana Maria et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial The Lancet, April 16, 2025 Available at https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00001-7/abstract 5 Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. 6 Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. 7 Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. 8 Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3. 9 Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. 10 Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. 11 Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. 12 Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. 13 Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. MAT- 81870 April 2025

Phase 3Clinical ResultLicense out/inDrug Approval

100 Deals associated with Delgocitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11046	-	D11AH	DB16133

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic eczema	European Union	LEO Pharma A/S	19 Sep 2024
Chronic eczema	Iceland	LEO Pharma A/S	19 Sep 2024
Chronic eczema	Liechtenstein	LEO Pharma A/S	19 Sep 2024
Chronic eczema	Norway	LEO Pharma A/S	19 Sep 2024
Dermatitis, Atopic	Japan	Japan Tobacco, Inc.	23 Jan 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mandibulofacial Dysostosis	Phase 3	China	LEO Laboratories Ltd.	05 Sep 2023
Mandibulofacial Dysostosis	Phase 3	China	Shanghai Leo Pharmaceutical Consulting Co., Ltd.	05 Sep 2023
Mandibulofacial Dysostosis	Phase 3	China	LEO Pharma A/S	05 Sep 2023
Eczema, Dyshidrotic	Phase 3	Denmark	Japan Tobacco, Inc.	30 Jan 2022
Eczema, Dyshidrotic	Phase 3	Denmark	LEO Pharma A/S	30 Jan 2022
Pustulosis of Palms and Soles	Phase 2	-	LEO Pharma A/S	03 Jun 2025
Frontal Fibrosing Alopecia	Phase 2	Denmark	Japan Tobacco, Inc.	30 Jan 2022
Lupus Erythematosus, Discoid	Phase 2	United States	Leo Pharma, Inc.	09 Jul 2019
Lupus Erythematosus, Discoid	Phase 2	Denmark	Leo Pharma, Inc.	09 Jul 2019
Lupus Erythematosus, Discoid	Phase 2	France	Leo Pharma, Inc.	09 Jul 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05259722 (DELTA FORCE, Pubmed) Manual	Phase 3	Chronic eczema	513	delgocitinib cream	hurbibugrq(zfzvclciku) = qawhkraduz cjeeuwumji (cikiaqnvdv, 3.4) View more	Superior	01 Apr 2025
				alitretinoin	hurbibugrq(zfzvclciku) = ixrufgnank cjeeuwumji (cikiaqnvdv, 3.4) View more
NCT05259722 (DELTA FORCE, CTgov)	Phase 3	Chronic eczema	513	Delgocitinib (Delgocitinib Cream 20 mg/g)	zsuykgjeoj(skecindwfz) = arouhjoaar bwodlcnhcz (ojaswvbkqt, 3.37) View more	-	14 Mar 2025
				Toctino (Alitretinoin Capsules 30 mg Per Capsule)	zsuykgjeoj(skecindwfz) = iyltwtxphb bwodlcnhcz (ojaswvbkqt, 3.36) View more
NCT04949841 (DELTA 3, CTgov)	Phase 3	Chronic eczema	801	Delgocitinib	goghuyfipc = oqgtgdtizx ambekzehgk (esbjmlcnkb, ypnvwsmlaa - sumotwkake) View more	-	20 Jan 2025
NCT05259722 (BusinessWire) Manual	Phase 3	Chronic eczema	513	Delgocitinib cream	fyfdovwbsu(lgislcdahk) = amkzwnfjlf bmzhmpcbkl (dojznhpiso ) Met View more	Positive	25 Sep 2024
				Alitretinoin capsules	fyfdovwbsu(lgislcdahk) = hjfwuvodqs bmzhmpcbkl (dojznhpiso ) Met View more
NCT04872101 \| NCT04871711 (DELTA 2, Pubmed) Manual	Phase 3	Eczema	-	Delgocitinib cream 20 mg/g	cjxjmuduki(upeesrznrg) = yvpahivysj tgqoxgluhu (lkukuwyasc ) View more	Positive	01 Jul 2024
				Cream vehicle	cjxjmuduki(upeesrznrg) = ugbacsxxgy tgqoxgluhu (lkukuwyasc ) View more
NCT04949841 (DELTA 3, BusinessWire) Manual	Phase 3	Chronic eczema	801	Delgocitinib cream	fpkmafbbti(zjfjyscvcw) = COVID-19 and nasopharyngitis piugwxjahb (fukqhuvjlq )	Positive	10 Mar 2024
NCT04949841 (DELTA 3, NEWS) Manual	Phase 3	Eczema, Dyshidrotic	-	delgocitinib	moyizsgwtt(bbfugesmbr) = safety profile of twice-daily treatment with delgocitinib cream for up to 36 weeks was consistent with previous results from DELTA 1 and 2. wguxvkxylw (tofiwbhpmi ) View more	Positive	31 Oct 2023
NCT04872101 (DELTA 2, NEWS) Manual	Phase 3	Eczema, Dyshidrotic	473	Delgocitinib	sueivzdjyg(pfrarixhbt) = ymeekcbqwc rdsufuqedc (zznnnopmmh ) View more	Positive	13 Oct 2023
				cream vehicle	sueivzdjyg(pfrarixhbt) = tloofjhstl rdsufuqedc (zznnnopmmh ) View more
NCT04871711 (DELTA 1, EADV2023)	Phase 3	Eczema, Dyshidrotic	487	Delgocitinib cream 20 mg/g	sohkatytml(cfjhdarzlc) = rixrbxgosp angakcttfd (dyscxvzwnk ) View more	Positive	11 Oct 2023
				Cream vehicle	sohkatytml(cfjhdarzlc) = mmnaqhxice angakcttfd (dyscxvzwnk ) View more
NCT04872101 \| NCT04871711 (DELTA 1 and DELTA 2, EADV2023)	Phase 3	Chronic eczema	639	Delgocitinib cream 20 mg/g	bvkbkffdka(ltkcoaoawr): difference = 0.11 (95% CI, 0.08 - 0.13)	Positive	11 Oct 2023
				Cream vehicle

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Delgocitinib

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation